Clinical trial
A Multicenter Phase IIb Randomised, Controlled Study of BLP25 Liposome Vaccine for Active Specific Immunotherapy of Non-Small Cell Lung Cancer
NCT00157209 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Phase IIb Randomised, Controlled Study of BLP25 Liposome Vaccine for Active Specific Immunotherapy of Non-Small Cell Lung Cancer
- Lead sponsor
- Merck KGaA, Darmstadt, Germany
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2000
- Completion date
- July 31, 2012
- Enrollment
- 171 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.